Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients
- Sponsor
- Omar Younis
- Study ID
- NCT05424315
- Phase
- PHASE2/PHASE3
- Status
- Completed
Conditions
- Anterior MI
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Dapagliflozin 10mg — DRUG10mg Tab once daily
- Glucose Tab — DRUGPlacebo Oral Tablet
Study Details
Sodium glucose co-transporter 2 inhibitors (SGLT2i) proved their favorable outcomes in heart failure. However, it is still unknown if their role extent into preventing heart failure, especially after acute myocardial infarction. This study aimed at identifying if there is such role for SGLT2i.
Key Dates
- Start date
- Oct 1, 2021
- Status verified
- Nov 2024
- Primary completion
- Apr 30, 2022
- Completion
- Apr 30, 2022
Study Design
- Enrollment
- 100 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Active Comparator: Intervention GroupParticipants will receive Dapagliflozin 10mg once daily.
- Placebo Comparator: Control GroupParticipants will receive a glucose tab once daily.
Primary Outcome Measure
A change in NT-proBNP levels from baseline to 12 weeks post-anterior STEMI [ Time Frame: 12 weeks ]